Reviewed by Michael Gill, B. Sc.
Image of Novo Nordisk Investigational Site in Birmingham, United States.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety

Cagrisema S.c. 2.4 Mg/2.4 Mgfor Obesity

Any Age
All Sexes
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
Phase 3
Recruiting
Quick Reply
Novo Nordisk Investigational Site (+45 Sites)Clinical Reporting Office dept. 2834Novo Nordisk A/S
Image of University of Alberta in Edmonton, Canada.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Family Navigation + Usual Carefor Obesity, Child

< 18
All Sexes
Our feasibility study will assess the feasibility and acceptability of Family Navigation (FN) to address attrition (dropout) in pediatric obesity management. Results from this study will help our team to plan a large randomized clinical trial to test the effectiveness of FN in reducing attrition. The investigators will enroll 108 6-to-17-year-olds enrolled in pediatric obesity management clinics in Calgary, AB and Mississauga, ON (Canada). One-half of the children will receive Family Navigation (FN) + Usual Care (UC) for 12 months; the other half will receive Usual Care only for 12 months. Overall, the study will take 2.5 years to complete. For children receiving FN, trained navigators will work with children and their families to reduce barriers that limit their access to health services and support. Navigators will offer extra services and resources, such as parking passes for clinic appointments and supportive text messages between appointments. FN is designed to complement the obesity management (Usual Care) received by children and their families. A Steering Committee with children, caregivers, clinicians, and researchers will be created to refine and improve our FN intervention throughout the study. By having better access to care, children and their families working with navigators may be less likely to drop out and more likely to attend more treatment appointments. Ultimately, the participants may be more likely to achieve success in managing obesity.
Recruiting
Has No Placebo
University of AlbertaGeoff Ball, PhD RD
25 Edmonton Clinical Trials Near Me
Top Cities for Edmonton Clinical Trials
Image of Edmonton in Alberta.
Edmonton
222Active Trials
University of AlbertaTop Active Site
Image of New York in New York.
New York
150Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site